The Coming Psychedelic Boom
Warning to all investors: There's a coming boom that might make the CBD craze look like an outdated investment.

NASDAQ:ADPT - Adaptive Biotechnologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $63.00
  • Forecasted Upside: 58.69 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$39.70
▼ -0.18 (-0.45%)

This chart shows the closing price for ADPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adaptive Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADPT

Analyst Price Target is $63.00
▲ +58.69% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Adaptive Biotechnologies in the last 3 months. The average price target is $63.00, with a high forecast of $74.00 and a low forecast of $55.00. The average price target represents a 58.69% upside from the last price of $39.70.

This chart shows the closing price for ADPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
Seattle Cannabis Blockbuster Set to Double Sales in Next 2 Years!
Thanks to a recent reorganization, acquisitions, and strategic partnerships, one Seattle cannabis blockbuster is poised for a massive expansion in the coming 24 months. With plans to double its annual sales in the next two years, this company’s shares could potentially skyrocket in value.

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Adaptive Biotechnologies.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2021Morgan StanleyLower Price TargetEqual Weight$60.00 ➝ $55.00High
3/9/2021The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$74.00 ➝ $63.00High
3/3/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$74.00 ➝ $63.00High
2/26/2021Morgan StanleyBoost Price TargetEqual Weight$46.00 ➝ $60.00Medium
1/19/2021BTIG ResearchBoost Price TargetPositive ➝ Buy$66.00 ➝ $74.00Low
11/12/2020BTIG ResearchBoost Price TargetBuy$60.00 ➝ $63.00High
11/11/2020JPMorgan Chase & Co.Reiterated RatingOverweight$50.00 ➝ $60.00High
11/11/2020Morgan StanleyBoost Price TargetEqual Weight$42.00 ➝ $46.00High
10/7/2020BTIG ResearchInitiated CoverageBuyLow
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$42.00High
8/11/2020William BlairReiterated RatingOutperformMedium
6/3/2020The Goldman Sachs GroupInitiated CoverageBuy$60.00Low
5/19/2020GuggenheimBoost Price TargetBuy$44.00 ➝ $50.00Low
4/17/2020BTIG ResearchReiterated RatingBuy$46.00High
7/23/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$46.00Medium
7/22/2019William BlairInitiated CoverageOutperform ➝ OutperformHigh
7/22/2019CowenInitiated CoverageOutperform ➝ OutperformHigh
7/22/2019GuggenheimInitiated CoverageBuy ➝ Buy$47.00High
7/22/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$45.00High
7/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight$45.00High
7/22/2019The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$32.00High
(Data available from 6/23/2016 forward)
Adaptive Biotechnologies logo
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $39.70
Low: $38.62
High: $40.40

50 Day Range

MA: $38.18
Low: $32.22
High: $44.59

52 Week Range

Now: $39.70
Low: $30.41
High: $71.25

Volume

484,864 shs

Average Volume

954,107 shs

Market Capitalization

$5.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Adaptive Biotechnologies?

The following sell-side analysts have issued reports on Adaptive Biotechnologies in the last twelve months: BTIG Research, JPMorgan Chase & Co., Morgan Stanley, The Goldman Sachs Group, Inc., William Blair, and Zacks Investment Research.
View the latest analyst ratings for ADPT.

What is the current price target for Adaptive Biotechnologies?

4 Wall Street analysts have set twelve-month price targets for Adaptive Biotechnologies in the last year. Their average twelve-month price target is $63.00, suggesting a possible upside of 62.4%. BTIG Research has the highest price target set, predicting ADPT will reach $74.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $55.00 for Adaptive Biotechnologies in the next year.
View the latest price targets for ADPT.

What is the current consensus analyst rating for Adaptive Biotechnologies?

Adaptive Biotechnologies currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADPT will outperform the market and that investors should add to their positions of Adaptive Biotechnologies.
View the latest ratings for ADPT.

What other companies compete with Adaptive Biotechnologies?

How do I contact Adaptive Biotechnologies' investor relations team?

Adaptive Biotechnologies' physical mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The company's listed phone number is 206-659-0067 and its investor relations email address is [email protected] The official website for Adaptive Biotechnologies is www.constructionpartners.net.

The Coming Psychedelic Boom
Warning to all investors: There's a coming boom that might make the CBD craze look like an outdated investment.